Strong Participation and Valuable Insights from FRANC2026 Pediatrics

May 8, 2026

The 29th Fresenius Kabi Advanced Nutrition Conference – FRANC2026 Pediatrics, held on April 24–25 in Bad Homburg, brought together healthcare professionals and Fresenius Kabi employees from around the world to exchange scientific insights and practical experience in pediatric and neonatal medical nutrition.

With 273 participants from 32 countries, the conference reached an even significantly broader international audience than previous editions. The hybrid format proved effective, enabling participation for healthcare professionals affected by travel or geopolitical constraints joining remotely.

The program was chaired by Dr. Kathleen Gura and Prof. Frank Jochum and supported by 11 international experts. 

Focus on clinical relevance and practical exchange

The FRANC2026 Pediatrics conference served not only as an educational platform, but also as a foundation for future international congress activities and subsequent regional and local initiatives.

The two-day program addressed medical nutrition therapy across pediatric and neonatal patient groups – from preterm infants to adolescents, in both hospital and home care settings. A new program structure introduced dedicated professional streams, with 19 focused breakout sessions tailored to neonatologists, pediatricians, and pharmacists. This ensured relevance for different clinical roles and allowed deeper discussion of real-world challenges.

Interactive formats played a central role, including clinical case discussions and expert-led breakout sessions, encouraging exchange of local practices and perspectives.

Key scientific takeaways

Across sessions and discussions, several core messages emerged:

  • Medical Nutrition Therapy (MNT) should be understood as a continuous approach from neonatal and pediatric intensive care to hospital and home settings.

  • Standardized Parenteral Nutrition can improve safety, quality and efficiency.

  • Lipids, including fish oil-containing intravenous lipid emulsions, are an essential component of PN and may reduce the risk of cholestasis.

  • In pediatrics, long-term PN remains a first-line MNT in short bowel syndrome and intestinal failure, with balanced lipid emulsions supporting the prevention of parenteral nutrition associated liver disease.

You are leaving nutritionevents.com 

Using this link will let you leave nutritionevents.com. In the event that the linked site is not under the control of Fresenius Kabi but under the control of a third party or an affiliate in the Fresenius group of companies, Fresenius Kabi shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Fresenius Kabi of the site.

Do you want to continue?

Accept